The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.
May 16th 2024
Patients with HIV who switched to a treatment regimen that included tenofovir alafenamide (TAF) showed improvement in serum markers for hepatic steatosis (HS) among other benefits.
Single-Tablet Regimens Produce Better HIV Virologic Response Than Multiple-Tablet Regimens
December 26th 2018According to a new study, single-tablet regimens may provide better virologic response and control than multiple-tablet regimens for people living with HIV, likely due to a lower pill burden and, subsequently, better medication adherence.
Read More
Diabetes, Cancer Interviews Among Most-Watched Videos of 2018
December 20th 2018Throughout the year, The American Journal of Managed Care® (AJMC®) offered a number of video programs, including Peer Exchange discussions and interviews, on a range of topics. Here are the most-watched videos published by AJMC® in 2018.
Read More
NIH Announces Funding for HIV Treatment, Prevention Research in Vulnerable Southern Counties
December 13th 2018The National Institutes of Health (NIH) said that it will fund a series of collaborations with medical research institutions in the region as part of a new initiative that will expand ongoing research at the NIH-funded Centers for AIDS Research, a group of HIV-focused research institutions focused on reducing the burden of HIV domestically and globally.
Read More
HIV-2 Just as Deadly as HIV-1, but at a Slower Rate
December 6th 2018A recent study compared the time to AIDS and mortality and the CD4 T-cell dynamics between HIV-1 and HIV-2, finding that both groups have a high probability of developing and dying from AIDS without antiretroviral treatment.
Read More
This Week in Managed Care: November 30, 2018
November 30th 2018This week, the top managed care news included a CMS plan for changes in drug coverage that brought a wave of criticism; a government task force recommended more people at risk for HIV take pre-exposure prophylaxis, known as PrEP; the American College of Cardiology issued an Expert Consensus Pathway on treatment of patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Watch
USPSTF Recommends Clinicians Prescribe HIV PrEP to All High-Risk Patients
November 22nd 2018The US Preventive Services Task Force (USPSTF) is recommending that clinicians offer the treatment to people at high risk of HIV, which will likely increase access to the treatment for those who need it most.
Read More
Cellular Proliferation Drives HIV Persistence During Treatment With ART
November 21st 2018According to a new study, cellular proliferation generates the majority of infected cells during antiretroviral therapy (ART), suggesting that reducing proliferation can decrease the size of the HIV reservoir and work toward a cure.
Read More
Provider Stigma Toward HIV Slows Prevention Goals
November 15th 2018As physicians have an essential role in the fight against HIV—leading patients through the care continuum—understanding HIV-related stigma among physicians can inform development of interventions to reduce this stigma and promote positive clinical outcomes.
Read More
Hispanics Living With HIV at Increased Risk of HPV-Related Cancers
November 6th 2018Hispanics living with HIV are at an increased risk of developing cancers caused by the human papillomavirus (HPV) compared to the general Hispanic population, and among people living with HIV, Hispanics are more likely to be diagnosed with cervical and penile cancer.
Read More
Researchers Propose Adding Viral Suppression Within 3 Months of HIV Diagnosis to HIV/AIDS Strategy
November 1st 2018Recognizing a need for an outcome indicator for those newly diagnosed with HIV, researchers have proposed including the percentage of newly diagnosed persons achieving viral suppression within 3 months of diagnosis.
Read More
Janssen Releases Long-Term AMBER Trial Data Supporting Safety, Efficacy of Symtuza for HIV
October 30th 2018Building on positive 48-week data, Janssen released 96-week data demonstrating high rates of virogolic suppression and tolerability among antiretroviral therapy-naïve adults with HIV-1.
Read More
Retention in HIV Care Decreases Over Time Following Release From Incarceration
October 26th 2018Following more than 1000 people living with HIV who were recently incarcerated, researchers observed that retention in care diminished significantly over time, but it was associated with HIV care during incarceration, health insurance, case management services, and early linkage to care post release.
Read More
Symtuza Achieves, Maintains Viral Suppression in Patients With HIV
October 9th 2018Treatment with Symtuza (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) results in and maintains high virologic suppression rates, according to study findings presented at the 2018 Infectious Disease Week conference held in San Francisco, California.
Read More